Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 6/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | CASP1 | P29466 | 2/20 | 0.32 |
| ▸ | CASP7 | P55210 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29199475 | 0.85 | SLC9A1 (0.47) | SLC9A1GRM2HTTALDH1A1CASP1 | |
| SCHEMBL29199466 | 0.82 | SLC9A1 (0.50) | SLC9A1GRM2ALDH1A1NR1H3TSHR | |
| SCHEMBL3801864 | 0.80 | SLC9A1 (0.51) | SLC9A1GRM2 | |
| SCHEMBL570412 | 0.77 | TDO2 (0.39) | CYP1A2CYP2D6ALDH1A1MAPK1KDM4E | |
| SCHEMBL3326163 | 0.77 | GRM2 (0.47) | SLC9A1GRM2ALDH1A1NR1H3KDM4E | |
| SCHEMBL3663636 | 0.74 | ALDH1A1 (0.52) | HTTALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL3705991 | 0.74 | GRM2 (0.42) | GRM2ALDH1A1KDM4EHSD17B10L3MBTL1 | |
| SCHEMBL29141982 | 0.74 | KDM4E (0.36) | ALDH1A1MAPK1KDM4EMAPTTSHR | |
| SCHEMBL14157278 | 0.72 | NPC1 (0.38) | NPC1 | |
| SCHEMBL570629 | 0.72 | CDK4 (0.37) | HTTALDH1A1KDM4ENPC1HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003030909-A1 | 2- AND 4-AMINOPYRIMIDINES N-SUBSTTITUDED BY A BICYCLIC RING FOR USE AS KINASE INHIBITORS IN THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-17 | — | — | WO | claimed |
| US-4132436-A | Recording material | FUJI PHOTO FILM CO., LTD. (JP) | 1979-01-02 | — | — | US | claimed |
| CN-114213331-B | URAT1 inhibitor and application thereof | 江苏新元素医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-110669107-B | Antibacterial peptide and preparation method thereof | 上海医药工业研究院 | 2024-04-02 | — | — | CN | disclosed |
| CN-108727267-B | URAT1 inhibitor and application thereof | 江苏新元素医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114213331-A | URAT1 inhibitor and application thereof | 江苏新元素医药科技有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-RE48622-E1 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | disclosed |
| EP-2935269-B1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2018-04-11 | — | — | EP | disclosed |
| US-9714248-B2 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2017-07-25 | — | — | US | disclosed |
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-06-01 | — | — | US | disclosed |
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2016-07-07 | — | — | US | disclosed |
| EP-2935269-A1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2015-10-28 | — | — | EP | disclosed |
| EP-2601208-B1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2015-02-11 | — | — | EP | disclosed |
| WO-2014096423-A1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2014-06-26 | — | — | WO | disclosed |
| EP-2690495-A1 | Lithographic printing plate precursor and plate making method thereof | Fujifilm Corporation (JP) | 2014-01-29 | — | — | EP | disclosed |
| EP-2601208-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | Graffinity Pharmaceuticals GmbH (DE) | 2013-06-12 | — | — | EP | disclosed |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| WO-2012017021-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2012-02-09 | — | — | WO | disclosed |
| US-4132436-A | Recording material | FUJI PHOTO FILM CO., LTD. (JP) | 1979-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | HAVCR2, TPMT, NFATC1 | SLC9A1 3902/4885GRM2 2805/4885CYP1A2 2465/4885 |
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | FCGR1A, FCGR2A, FCGR3B | SLC9A1 4497/4885GRM2 1967/4885CYP1A2 4537/4885 |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | FCGR1A, FCGR2A, FCER2 | SLC9A1 2326/4885GRM2 134/4885CYP1A2 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.